The Simplest Pharmacokinetic Equation in ADC (Antibody Drug Conjugate) or PDC (Peptide Drug Conjugate) Research
Heejin Park
Heejin Park, Department of Organic Chemistry, Eotvos Lorand University, Budapest, Hungary.
Manuscript received on 10 July 2022 | Revised Manuscript received on 09 August 2022 | Manuscript Accepted on 15 August 2022 | Manuscript published on 30 August 2022 | PP: 1-4 | Volume-2 Issue-5, August 2022 | Retrieval Number: 100.1/ijapsr.C4017043323 | DOI: 10.54105/ijapsr.C4017.082522
Open Access | Editorial and Publishing Policies | Cite | Mendeley | Indexing and Abstracting
© The Authors. Published by Lattice Science Publication (LSP). This is an open-access article under the CC-BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/)
Abstract: It has been known that devising a suitable pharmacokinetic equation in ADC (Antibody Drug Conjugate) or PDC (Peptide Drug Conjugate) is exceptionally difficult as there are many factors which affect to distribution of this drug in vivo. Some address the three portions, antibody, linker, and drug can be differently behave in the bloodstream makes them difficult to monitor it. Also other issues like solubility, liphophilicity (cell penetration ability), molecular weight, ionization, enzyme degradation, renal clearance, aggregation, and poor adsorption are mentioned as a big barrier to devise a delicate pharmacokinetic equation. Herein, the most simple mathematic pharmacokinetic equation could be argued with the following three hypotheses in ADCs or PDCs development; all drugs are attached only the target cells not any other sites till their complete function, the speed of drug working is constant with time, and all cancer cells have equal shape, mass, and size placed in a list of petri dishes with same number in the same environment. Though in reality, these are not being kept, but knowing the parameters of pharmacokinetic equation could bring about a rough estimation of distribution when the synthesized drug is administrated to the selected animal at the stage of animal test. Thus, the additional modifications which reflect the real status could be developed from this backbone equation, Y= -(r/2p) X + r/2 (p = time(minutes), r/2 = demolished amount of cancer cells(gram)) in the near future. I expect many real problems like solubility, liphophilicity (cell penetration ability), molecular weight, ionization, enzyme degradation, renal clearance, aggregation, and poor adsorption, etc. could be discussed from this suggested equation model.
Keywords: Antibody-Drug-Conjugate (ADC), Peptide-Drug- Conjugate (PDC), Pharmacodynamic, IC50, Pharmacokinetic, Distribution, Bio-Distribution
Scope of the Article: Pharmacokinetics